Abstracts tagged "axial spondyloarthritis"

Abstract Number: 1292 • 2016 ACR/ARHP Annual Meeting
Performance of 18fluoride Sodium Positron Emission Tomography with Computed Tomography to Assess Inflammatory and Structural Sacroiliitis Respectively on Magnetic Resonance Imaging and Computed Tomography in Axial Spondyloarthritis
Marie Raynal¹, ouichka remy², Julian Melchior¹, Isabelle Chary-Valckenaere³, Willy Ngueyon Sime⁴, Walter P. Maksymowych⁵, Robert G. Lambert⁶ and Damien Loeuille³, ¹Rheumatology, CHRU Nancy, Nancy, France, ²rheumatology, CHRU Nancy, Vandoeuvre les Nancy, France, ³Rheumatology, CHRU Nancy, Vandoeuvre les Nancy, France, ⁴University of Lorraine, Nancy, France, ⁵Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: to assess increased SIJ uptakes on 18-FNa (an osteoblastic tracer) PET/CT according to a qualitative and quantitative approach and to compare with MRI SIJ…
Abstract Number: 1667 • 2016 ACR/ARHP Annual Meeting
Diagnostic Value of Anti-CD74 Antibodies in Axial Spondyloarthritis: Results from a Population with Low HLA-B27 Prevalence Background
Nelly Ziade¹, Fouad Fayad¹, Iyad Mallak², Georges Merheb³, Torsten Witte⁴ and Xenofon Baraliakos⁵, ¹Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ²Radiology, Hotel-Dieu de France and Saint-Joseph University, Beirut, Lebanon, ³Internal Medicine, Notre Dame des Secours University Hospital, Jbeil, Lebanon, ⁴Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ⁵Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is still frequently diagnosed late and its pathogenesis is still unclear. Although a strong genetic association of axSpA with HLA-B27 is…
Abstract Number: 691 • 2015 ACR/ARHP Annual Meeting
Standards for the Classification of Non-Radiographic Axial Spondyloarthritis: A European Real World Study
Tim Holbrook¹, Robert Wood¹, Christopher Black², Xiaohan Hu² and Sumesh Kachroo², ¹Adelphi Real World, Macclesfield, United Kingdom, ²CORE, Merck & Co., Inc., Rahway, NJ
Background/Purpose: Classification of non-radiographic axial spondyloarthritis (nr-axSpA) requires the presence of Assessment of Spondyloarthritis international Society (ASAS) criteria for AxSpA, without radiologic evidence of sacroiliitis…
Abstract Number: 2878 • 2015 ACR/ARHP Annual Meeting
Treating Axial Spondyloarthritis to Target: Influence of the Population Characteristics and Comorbidities in Reaching Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Tnfalpha Inhibitors Agents
Sara Monti, Veronica Codullo, Vittorio Grosso, Silvia Breda, Carlomaurizio Montecucco and Roberto Caporali, Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy
Background/Purpose: The treat to target strategy (T2T), aiming at inactive disease (ID), has become the recommended approach also in the field of axial-SpA (axSpA) (1). …
Abstract Number: 696 • 2015 ACR/ARHP Annual Meeting
Current and Past Smoking Are Associated with Functional Impairement and Increased Disease Activity in Axial Spondyloarthritis: Systematic Review and Meta-Analysis
Kristina SCHREIBER¹, Thomas Barnetche², BG Combe³, Jacques Morel¹ and Claire I. Daien¹, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Lapeyronie, Montpellier, France
Background/Purpose: The influence of smoking on the development of rheumatoid arthritis, the severity of the disease and the response to treatment is well established. The…
Abstract Number: 2885 • 2015 ACR/ARHP Annual Meeting
Long-Term Effects of Etanercept on Patient-Reported Outcomes in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Results of a Phase III Study
Filip van Den Bosch^1,2, Edit Drescher³, Jan Rosa⁴, Ronald Pedersen⁵, Randi Bonin⁶, Bonnie Vlahos⁷, Jack F Bukowski⁶ and Sameer Kotak⁸, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁴Mediscan Group, Prague, Czech Republic, ⁵Department of Biostatistics, Pfizer, Collegeville, PA, ⁶Clinical Affairs, Pfizer, Collegeville, PA, ⁷GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ⁸Global Health and Value, Pfizer, New York, NY
Background/Purpose: In patients with active, NSAID-resistant, non-radiographic axial spondyloarthritis (nr-axSpA) who participated in the multiphase, randomized, placebo (PBO)-controlled EMBARK study (ClinicalTrials.gov identifier: NCT01258738), health-related quality-of-life…
Abstract Number: 697 • 2015 ACR/ARHP Annual Meeting
Identification Methods for Axial Spondyloarthritis in American Veterans
Jessica Walsh¹, Jianwei Leng², Brian Breviu³, Daniel Clegg⁴, Tao He² and Brian Sauer⁵, ¹Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ²Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ³Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁴Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁵Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Current methods for identifying people with axial spondyloarthritis (AxSpA) in large datasets are inadequate because billing codes for most types of spondyloarthrtis (SpA) do…
Abstract Number: 2893 • 2015 ACR/ARHP Annual Meeting
Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis after 16 Weeks of Golimumab Treatment
Walter Maksymowych¹, Sean P. Curtis², Maxime Dougados³, Gina Bergman², Susan Huyck², Anjela Tzontcheva² and Joachim Sieper⁴, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Merck & Co., Inc., Kenilworth, NJ, ³Paris-Descartes University, Paris, France, ⁴University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: Chronic inflammation, back pain, and progressive spinal stiffness associated with axial spondyloarthritis (axSpA) can decrease quality of life (QoL). The purpose of this study…
Abstract Number: 709 • 2015 ACR/ARHP Annual Meeting
Progression of Patients with Non-Radiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population-Based Cohort Study
Runsheng Wang¹, Sherine Gabriel² and Michael M. Ward¹, ¹NIH/NIAMS, Bethesda, MD, ²Division of Rheumatology; Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: The long-term outcome of patients with non-radiographic axial spondyloarthritis (nr-axSpA) is unclear, particularly whether few or most progress to ankylosing spondylitis (AS). Our objective…
Abstract Number: 713 • 2015 ACR/ARHP Annual Meeting
Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Treatment Results
Maxime Dougados¹, Désirée van der Heijde², Joachim Sieper³, Juergen Braun⁴, Gustavo Citera⁵, Filip van Den Bosch^6,7, Ronald Pedersen⁸, Randi Bonin⁹, Heather Jones¹⁰, Lisa Marshall¹⁰, Sameer Kotak¹¹, Isabelle Logeart¹², Bonnie Vlahos¹³, Jack F Bukowski⁹ and Walter Maksymowych¹⁴, ¹Rheumatology Department, Hôpital Cochin, Paris, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Rheumatology, Consultorios Reumatológicos Pampa, Buenos Aires, Argentina, ⁶Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸Department of Biostatistics, Pfizer, Collegeville, PA, ⁹Clinical Affairs, Pfizer, Collegeville, PA, ¹⁰Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ¹¹Global Health and Value, Pfizer, New York, NY, ¹²Medical Affairs, Pfizer, France, Paris, France, ¹³GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ¹⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: In the multiphase, randomized, placebo (PBO)-controlled EMBARK study (ClinicalTrials.gov identifier: NCT01258738), clinical signs/symptoms and MRI-measured inflammation were evaluated in patients with early, active non-radiographic…
Abstract Number: 714 • 2015 ACR/ARHP Annual Meeting
Baseline MRI and CRP As Predictors of Response to Etanercept in the Management of Patients with Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Matthew A. Brown¹, Paul A. Bird², Philip C. Robinson³, Philip J. Mease⁴, Filip van Den Bosch⁵, Christine Surian⁶, Zirke Wiid⁶, Heather Jones⁷, Annette Szumski⁸ and Lisa Marshall⁷, ¹Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ²University of New South Wales, Sydney, Australia, ³University of Queensland & Royal Brisbane and Women's Hospital, Brisbane, Australia, ⁴Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Pfizer Australia, Sydney, Australia, ⁷Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁸Department of Biostatistics, Pfizer, Collegeville, PA
Background/Purpose: Treatment with tumor necrosis factor α (TNFα) inhibitors has been shown to be effective in improving disease activity and functional capacity in patients with…
Abstract Number: 976 • 2015 ACR/ARHP Annual Meeting
The Reason of Discontinuation of a First TNF Inhibitor Affects Drug Retention of a Second Anti-TNF Agent in Axial Spondyloarthritis
Adrian Ciurea¹, Pascale Exer², Ulrich Weber^3,4, Giorgio Tamborrini⁵, Beate Steininger¹, Rudolf O. Kissling⁶, Jürg Bernhard⁷ and Almut Scherer⁸, ¹Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Private rheumatology practice, Basel, Switzerland, ³Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁴Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵Department of Rheumatology, University Hospital, Zurich, Switzerland, ⁶Division of Rheumatology, Balgrist University Hospital, Zurich, Switzerland, ⁷Rheumatology and Rehabilitation, Bürgerspital Solothurn, Solothurn, Switzerland, ⁸SCQM Foundation, Zurich, Switzerland
Background/Purpose: Conflicting results have been demonstrated in axial spondyloarthritis (axSpA) with regard to whether effectiveness of a second (2°) TNFi depends on the reason of…
Abstract Number: 1231 • 2015 ACR/ARHP Annual Meeting
The Prevalence of Non-Radiographic Axial Spondyloarthritis Among Patients with Inflammatory Back Pain in Rheumatology Practices
Rubén Burgos-Vargas¹, James Wei², Mahboob U Rahman³, Nurullah Akkoc⁴, Syed A. Haq⁵, Mohammed Hammoudeh⁶, Ehab Mahgoub⁷, Ena Singh⁸, Lyndon Llamado⁹, Khalid Shirazy¹⁰, Sameer Kotak¹¹, Connie Hammond⁷, Ronald Pedersen¹², Qi Shen¹³ and Bonnie Vlahos¹³, ¹Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ²Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan, ³Perelman School of Medicine, University of Pennsylvania, Philadephia, PA, ⁴Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, ⁵Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, ⁶Medicine, Hamad Medical Corporation, Doha, Qatar, ⁷Pfizer, Collegeville, PA, ⁸500 Arcola Road, Pfizer, Collegeville, PA, ⁹Pfizer, Makati, Philippines, ¹⁰Pfizer, Dubai, United Arab Emirates, ¹¹Global Health and Value, Pfizer, New York, NY, ¹²Department of Biostatistics, Pfizer, Collegeville, PA, ¹³GIPB - Clinical Sciences, Pfizer, Collegeville, PA
Background/Purpose: The diagnosis of Ankylosing Spondylitis (AS) is delayed by >10 years after the symptoms develop, as by definition the modified NY criteria for classification…
Abstract Number: 1283 • 2015 ACR/ARHP Annual Meeting
The Burden of Non-Radiographic Axial Spondyloarthritis from the Employer Perspective: A Real World European Study
Tim Holbrook¹, Robert Wood¹, Christopher Black², Xiaohan Hu² and Sumesh Kachroo², ¹Adelphi Real World, Macclesfield, United Kingdom, ²CORE, Merck & Co., Inc., Rahway, NJ
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) is a burdensome disease to both the patient and the healthcare system, as previous research has indicated. However, the societal…
Abstract Number: 1284 • 2015 ACR/ARHP Annual Meeting
Burden of Illness Associated with Non-Radiographic Axial Spondyloarthritis: A European Real World Database Analysis from the Clinical and Healthcare System Perspective
Tim Holbrook¹, Robert Wood¹, Christopher Black², Xiaohan Hu² and Sumesh Kachroo², ¹Adelphi Real World, Macclesfield, United Kingdom, ²CORE, Merck & Co., Inc., Rahway, NJ
Background/Purpose: Whilst the burden of axial spondyloarthritis (axSpA) is well known, non-radiographic (nr)-axSpa has only recently been identified as a distinct spondyloarthritic indication with its…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].